
Mallinckrodt plc – OTC:MNKKQ
Mallinckrodt stock price today
Mallinckrodt stock price monthly change
Mallinckrodt stock price quarterly change
Mallinckrodt key metrics
Market Cap | N/A |
Enterprise value | 2.71B |
P/E | N/A |
EV/Sales | 2.93 |
EV/EBITDA | -2.52 |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -21.61 |
Revenue | 924.6M |
EBITDA | -1.07B |
Income | -780.6M |
Revenue Q/Q | -29.77% |
Revenue Y/Y | -62.80% |
Profit margin | -84.4% |
Oper. margin | -27.48% |
Gross margin | -36.25% |
EBIT margin | -27.48% |
EBITDA margin | -116.26% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeMallinckrodt stock price history
Mallinckrodt stock forecast
Mallinckrodt financial statements
Sep 2021 | 507.2M | -269M | -53.04% |
---|---|---|---|
Dec 2021 | -457.2M | -197.6M | 43.22% |
Mar 2022 | 490.9M | -120.2M | -24.49% |
Jul 2022 | 383.7M | -193.8M | -50.51% |
Sep 2021 | 9158000000 | 8.64B | 94.39% |
---|---|---|---|
Dec 2021 | 329100000 | 491.3M | 149.29% |
Mar 2022 | 8704900000 | 8.50B | 97.76% |
Jul 2022 | 6485900000 | 4.34B | 67.03% |
Sep 2021 | 82.4M | -8.9M | -4.7M |
---|---|---|---|
Dec 2021 | 0 | 0 | 0 |
Mar 2022 | 49.2M | -23.4M | -4.6M |
Jul 2022 | -691.5M | -9.6M | -274.1M |
Mallinckrodt alternative data
Aug 2023 | 2,778 |
---|---|
Sep 2023 | 2,778 |
Oct 2023 | 2,778 |
Nov 2023 | 2,778 |
Dec 2023 | 2,778 |
Jan 2024 | 2,778 |
Feb 2024 | 2,778 |
Mar 2024 | 2,778 |
Apr 2024 | 2,778 |
May 2024 | 2,778 |
Jun 2024 | 2,778 |
Jul 2024 | 2,778 |
Mallinckrodt other data
Period | Buy | Sel |
---|---|---|
Aug 2021 | 0 | 7180 |
Mar 2022 | 0 | 34065 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Sale | REED JOANN A director | Ordinary Shares | 22,087 | $0.12 | $2,584 | ||
Sale | REED JOANN A director | Ordinary Shares | 11,978 | $0.12 | $1,401 | ||
Sale | O'NEILL HUGH M. officer: EVP & Ch.. | Ordinary Shares | 2,100 | $0.26 | $538 | ||
Sale | NORTON DAVID Y director | Ordinary Shares | 5,080 | $0.26 | $1,336 | ||
Sale | PAYA CARLOS V director | Ordinary Shares | 16,614 | $0.4 | $6,712 | ||
Sale | CARROLL J MARTIN director | Ordinary Shares | 31,398 | $0.4 | $12,591 | ||
Sale | CASEY MARK J officer: EVP and .. | Ordinary Shares | 15,291 | $0.45 | $6,881 | ||
Sale | NORTON DAVID Y director | Ordinary Shares | 5,080 | $0.4 | $2,052 | ||
Sale | NORTON DAVID Y director | Ordinary Shares | 21,807 | $0.43 | $9,464 | ||
Sale | CARLUCCI DAVID R director | Ordinary Shares | 16,020 | $0.14 | $2,195 |
Insider | Compensation |
---|---|
Mr. Mark Christopher Trudeau (1961) Pres, Chief Executive Officer & Director | $14,890,000 |
Dr. Steven J. Romano M.D. (1959) Executive Vice President & Chief Scientific Officer | $4,780,000 |
Mr. Hugh M. O'Neill (1963) Executive Vice President & Chief Commercial and Operations Officer | $4,730,000 |
Mr. Mark J. Casey (1963) Executive Vice President & Chief Legal Officer | $4,380,000 |
Mr. Bryan M. Reasons (1967) Executive Vice President & Chief Financial Officer | $4,100,000 |
-
What's the price of Mallinckrodt stock today?
One share of Mallinckrodt stock can currently be purchased for approximately $0.02.
-
When is Mallinckrodt's next earnings date?
Unfortunately, Mallinckrodt's (MNKKQ) next earnings date is currently unknown.
-
Does Mallinckrodt pay dividends?
No, Mallinckrodt does not pay dividends.
-
What is Mallinckrodt's stock symbol?
Mallinckrodt plc is traded on the OTC under the ticker symbol "MNKKQ".
-
What is Mallinckrodt's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of Mallinckrodt?
Shares of Mallinckrodt can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Mallinckrodt's key executives?
Mallinckrodt's management team includes the following people:
- Mr. Mark Christopher Trudeau Pres, Chief Executive Officer & Director(age: 64, pay: $14,890,000)
- Dr. Steven J. Romano M.D. Executive Vice President & Chief Scientific Officer(age: 66, pay: $4,780,000)
- Mr. Hugh M. O'Neill Executive Vice President & Chief Commercial and Operations Officer(age: 62, pay: $4,730,000)
- Mr. Mark J. Casey Executive Vice President & Chief Legal Officer(age: 62, pay: $4,380,000)
- Mr. Bryan M. Reasons Executive Vice President & Chief Financial Officer(age: 58, pay: $4,100,000)
-
How many employees does Mallinckrodt have?
As Jul 2024, Mallinckrodt employs 2,778 workers.
-
When Mallinckrodt went public?
Mallinckrodt plc is publicly traded company for more then 12 years since IPO on 17 Jun 2013.
-
What is Mallinckrodt's official website?
The official website for Mallinckrodt is mallinckrodt.com.
-
How can i contact Mallinckrodt?
Mallinckrodt can be reached via phone at +353 1 696 0000.
Mallinckrodt company profile:

Mallinckrodt plc
mallinckrodt.comOTC
2,778
Drug Manufacturers - Specialty & Generic
Healthcare
Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, pulmonology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes; and gastrointestinal products. It offers Acthar Gel, a repository corticotropin injection for rheumatoid arthritis, infantile spasms, systemic lupus erythematosus, multiple sclerosis, systemic dermatomyositis, symptomatic sarcoidosis, severe acute and chronic allergic, and inflammatory diseases; INOmax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Therakos photopheresis, an immunotherapy treatment platform; Amitiza for constipation; and StrataGraft for the treatment of adults with deep partial-thickness burns. The company is also developing Terlipressin for the treatment of hepatorenal syndrome; and SLN 501 is a ribonucleic acid silencing therap. In addition, it provides specialty generic drugs and active pharmaceutical ingredients. The company markets its branded products to physicians, respiratory therapists, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. Mallinckrodt plc has collaboration with Silence Therapeutics plc to develop and commercialize ribonucleic acid interference drug targets. The company was founded in 1867 and is based in Dublin, Ireland. On October 12, 2020, Mallinckrodt plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Dublin, 15
CIK: 0001567892
ISIN: IE00BBGT3753
: